Who owns SABS?
Institutional ownership of SAB Biotherapeutics Inc. from Form 13F, Q2 2026
87 institutional managers reported holding SAB Biotherapeutics Inc. (SABS) in Form 13F filings for Q2 2026, with 68,398,064 shares worth $267M. The largest reported holder was Caligan Partners LP. Managers that filed both quarters cut a net 1,568,830 shares (-2.3%). 31 opened new positions and 21 sold out.
- Funds holding
- 87
- Value held
- $267M
- New / sold out
- 31 / 21
- Net shares, same filers
- -2.3%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of SABS
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| Caligan Partners LP | $31.1M | 11.6% | 7,967,207 | Unchanged |
| Vivo Capital, LLC | $28.5M | 10.7% | 7,299,909 | Trimmed |
| Perceptive Advisors LLC | $25.8M | 9.7% | 6,627,501 | Added |
| Adage Capital Partners GP, L.l.c. | $25.0M | 9.4% | 6,405,553 | Added |
| Ra Capital Management, L.p. | $17.2M | 6.4% | 4,401,500 | Unchanged |
| Balyasny Asset Management L.P. | $14.7M | 5.5% | 3,760,439 | Unchanged |
| BlackRock, Inc. | $12.0M | 4.5% | 3,066,016 | Added |
| Vanguard Capital Management LLC | $11.6M | 4.3% | 2,972,929 | Added |
| Commodore Capital LP | $11.2M | 4.2% | 2,870,000 | Trimmed |
| Millennium Management LLC | $10.7M | 4.0% | 2,749,087 | Trimmed |
| Spruce Street Capital LP | $8.6M | 3.2% | 2,198,502 | Unchanged |
| Sessa Capital IM, L.P. | $8.6M | 3.2% | 2,198,457 | Unchanged |
| Affinity Asset Advisors, LLC | $5.9M | 2.2% | 1,525,000 | Added |
| Boothbay Fund Management, LLC | $5.8M | 2.2% | 1,481,660 | Unchanged |
| Geode Capital Management, LLC | $5.0M | 1.9% | 1,277,185 | Added |
| Woodline Partners LP | $4.6M | 1.7% | 1,180,355 | Trimmed |
| Ensign Peak Advisors, Inc | $4.6M | 1.7% | 1,172,641 | Trimmed |
| Propel Bio Management, LLC | $4.2M | 1.6% | 1,076,578 | Added |
| Soleus Capital Management, L.P. | $3.5M | 1.3% | 900,000 | Trimmed |
| Seven Fleet Capital Management LP | $2.9M | 1.1% | 736,077 | Added |
| Ameriprise Financial Inc | $2.4M | 0.9% | 611,019 | Trimmed |
| State Street Corp | $2.1M | 0.8% | 530,831 | Added |
| Susquehanna International Group, LLP | $1.7M | 0.6% | 438,515 | New |
| DV Equities, LLC | $1.6M | 0.6% | 400,000 | First report |
| AWM Investment Company, Inc. | $1.5M | 0.5% | 375,000 | Trimmed |
Share of 13F holdings is each fund's shares as a share of the 68,398,064 SABS shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Adage Capital Partners GP, L.l.c. Added+$11.7M
- BlackRock, Inc. Added+$10.8M
- Geode Capital Management, LLC Added+$3.8M
- Affinity Asset Advisors, LLC Added+$3.7M
- Seven Fleet Capital Management LP Added+$2.5M
- Vanguard Capital Management LLC Added+$1.9M
- State Street Corp Added+$1.8M
- Susquehanna International Group, LLP New+$1.7M
- UBS Group AG Added+$1.2M
- Polymer Capital Management (HK) LTD New+$1.2M
Biggest sellers in Q2 2026
- Vivo Capital, LLC Trimmed-$16.1M
- Woodline Partners LP Trimmed-$6.5M
- Commodore Capital LP Trimmed-$6.0M
- Jefferies Financial Group Inc. Sold out-$3.5M
- Ameriprise Financial Inc Trimmed-$3.4M
- Blackstone Inc. Sold out-$3.3M
- ExodusPoint Capital Management, LP Sold out-$2.9M
- Monashee Investment Management LLC Sold out-$1.9M
- Marshall Wace, LLP Sold out-$1.8M
- Stempoint Capital LP Trimmed-$1.6M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $48.4M and sold $54.2M; 25 added and 16 trimmed.
Schedule 13D and 13G filings on SABS
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-08-12Adage Capital Management, L.P. SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2026-05-15Caligan Partners LP SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2026-05-15BALYASNY ASSET MANAGEMENT L.P. SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2026-05-01MILLENNIUM MANAGEMENT LLC SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2026-01-22PERCEPTIVE ADVISORS LLC SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2025-11-14Woodline Partners LP SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
- 2025-10-03RA CAPITAL MANAGEMENT, L.P. SCHEDULE 13D filed by SAB Biotherapeutics Inc.Schedule 13D
- 2025-10-03Commodore Capital LP SCHEDULE 13G filed by SAB Biotherapeutics Inc.Schedule 13G
Questions about SABS ownership
- Who owns SABS stock?
- 87 institutional investment managers reported SABS positions in their Form 13F filings for Q2 2026, holding 68,398,064 shares worth $267M in total. Caligan Partners LP reported the largest position.
- Are funds buying or selling SABS?
- In Q2 2026, 31 managers opened new SABS positions, 25 added, 16 trimmed and 21 sold out. Managers that filed in both quarters sold a net 1,568,830 shares.
- How current is this SABS institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to SABS by CUSIP. Options are left out. SABS news and filings · SABS insider trades · Top funds